Chemotherapy for advanced breast cancer is palliative, not curative, in intent. A variety of cytotoxic agents are active and often used in combination, with objective response rates from 40% to 60% frequently being reported, with median durations of 6 to 12 months Muss et al., 1978; Steiner et al., 1983; Tormey et al., 1984; Perry et al., 1987; Coates et al., 1987; Italian Multicentre Breast Study with Epirubicin, 1988; Namer et al., 1990; Carmo-Pereira et al., 1991; Richards et al., 1992) . Whilst a response is likely to be associated with a reduction in symptoms, this is to a variable extent counter-balanced by toxic effects of treatment. It would, therefore be of value to be able to predict which patients are likely to respond, and to spare patients with little or no chance of benefit from the rigours of treatment. This applies both to the selection of patients for first line chemotherapy and to the selection of patients suitable for second or third line chemotherapy after progression following earlier treatment. Unfortunately, reliable predictive tests are not currently available.
The aim of this study was to evaluate the parameters which may influence response to chemotherapy including characteristics of the tumour at presentation, the number and sites of metastatic disease, the treatment regimen employed and the efficacy of earlier chemotherapy treatments. We have reviewed data from all the patients at the Guy's Breast Unit who received at least one chemotherapy regimen for advanced breast cancer over the 16 year period to 1991. We sought to identify factors of value in predicting response to chemotherapy which may be of use in selecting appropriate treatment for individual patients.
Patients and methods
Between 1975 and 1991 a total of 1756 patients with inoperable locally recurrent or metastatic breast cancer were managed at the Guy's Hospital Breast Unit. In general, the policy adopted within the Unit has been to manage asymptomatic disease expectantly. Systemic therapy is given to patients with symptomatic progressive disease, and sometimes as prophylaxis against anticipated complications, which cannot be controlled by local measures (i.e. surgery or radiotherapy). Chemotherapy is usually reserved for the treatment of disease whcih can no longer be controlled by endocrine treatment, except in cases of rapidly progressive disease when a response to endocrine treatment is considered unlikely.
This report concerns the outcome from the time of start of chemotherapy for the 758 patients who have received at least one chemotherapy regimen. A variety of chemotherapy regimens were used, often in clinical trials, the results of which have previously been reported. These have included doxorubicin (60-75 mg m-2 given 3 weekly) either alone or with vincristine Steiner et al., 1983; Richards et al., 1992) , doxorubicin 25 mg m-2 given weekly (Richards et al., 1992) , doxorubicin combined with mitomycin C (Amiel et al., 1984) , epirubicin (90-120 mg m2) given 3 weekly (Carmo-Pereira et al., 1991) , epirubicin 25 mg m-2 weekly in patients with abnormal liver biochemistry (Twelves et al., 1989; Twelves et al., 1991) , mitozantrone 12 mg m-2 3 weekly (Coleman et al., 1984) , various combinations of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) (Engelsman et al., 1991) , and mitomycin C with vinblastine (MMC and Vinb) (Radford et al., 1985) .
Response was assessed by UICC criteria Statistical methods Survival (S) and relapse free survival (RFS) were calculated by the method of Kaplan and Meier (Kaplan & Meier, 1958) , with significance being determined using the log-rank test (Peto et al., 1977) , and multivariate analysis being undertaken with Cox's proportional hazards model (Cox, 1972 patients from the start of chemotherapy was 7.9 months. For responders median survival was 13.3 months, compared with 10.6 months for those with stable disease and 2.5 months for those with progressive disease.
Multivariate analysis of factors predicting for first response is shown in Table IV (Table IV) . However, it may still result from the patient selection policy, since these were not randomised studies. The response rate for patients with liver metastases was 32%, which was similar to that for other sites. However, a lower proportion (22%) of patients with liver metastases had stable disease (Table IV) and the median survival from start of chemotherapy for patients with liver metastases (4.5 months) was significantly shorter than that for patients without liver metastases (9.8 months; P <0.0001). Although nodal status showed a significant correlation with response, since some 18 possible prognostic factors were considered, and the P-value was only 0.05, this result should be treated with caution. (Figure 2 ). Time to progression was, however, the same for patients with local disease, distant disease or both (Figure 3) .
A number of factors were related to survival following first-line chemotherapy (Table VI) . Again, the significance of the different treatment regimens should be viewed with caution, both because of the barely significant P-values, and because of the non-randomised nature of the studies. Otherwise factors were the same as those which predicted time to progression, but with a number of additions. In particular, histological grade, and to a lesser extent age, both appeared to have prognostic significance. Survival was also better for those having local as opposed to distant disease at the time of treatment.
The survival and time to progression of patients presenting initially with locally advanced disease was similar to that of the group as a whole. Furthermore, excluding this group from the analysis made only very minor differences to the results, and the analyses presented therefore include these patients. were found in this analysis. However, in 181 patients where response to both first line and second line treatment was assessed (Table VIII) response to prior chemotherapy did influence the likelihood of response to second line chemotherapy. Seventeen of 70 (24%) patients who achieved complete response (CR) or partial response (PR) with first line chemotherapy responded to second line treatment, compared with 13 of 111 (12%) who had not achieved an objective response with first line treatment (P = 0.04). Median time to progression (TTP) following second line chemotherapy was 2.5 months with only 15% of patients having TTP longer than 6 months and only 5% having TTP longer than 12 months (Figure 4) . Median TTP for responders to second line chemotherapy (6.5 months) was longer than that for patients with SD (3.7 months; P<0.001). However, time to progression following second line treatment did not appear to be related to response to first line chemotherapy ( Figure 5 ) or to first TTP. Those with first TTP longer than the median had similar second TTP to those with shorter TTP following first chemotherapy ( Figure  6 ).
Response was assessable in 49 of 58 (84%) patients who received third line chemotherapy. Response rates and time to progression for those who received such treatment were similar to those observed for second line treatment (Table  VII and Figure 4 ). Of the 23 assessable patients receiving third line chemotherapy having shown no previous response with 1st or 2nd line treatment five (22%) showed an objective response.
Discussion
The primary aim of systemic treatment for patients with metastatic breast cancer is to control the disease and thereby to relieve symptoms and improve quality of life. The impact of chemotherapy on survival has never been directly assessed in this group of patients because of the difficulties inherent in conducting randomised trials with a 'no chemotherapy' arm. While it is likely that some patients survive longer as a result of receiving chemotherapy, the survival benefit attributable to chemotherapy remains uncertain. It is therefore essential that the potential benefits of systemic therapy should be carefully weighed against the likely toxicities. Achievement of objective response is associated with improvement in symptoms, and performance status (Baum et al., 1980) . Identification of patients who are likely to respond to chemotherapy therefore remains an important goal.
Most reports of outcome following chemotherapy for metastatic breast cancer are concerned with patients entered into clinical trials with strict eligibility criteria. In contrast to this we have examined the outcome for all patients who received chemotherapy at a single institution. Only 53% of the patients who have died with metastatic breast cancer had received chemotherapy for advanced disease, whereas most (74%) had received endocrine therapy. This reflects the policy adopted in this unit, which has generally been to give endocrine therapy ahead of chemotherapy, except in patients with a pattern of metastatic disease which is considered to be imminently life threatening.
The response rate (34%) to first line chemotherapy in this unselected series was, not surprisingly, lower than that frequently reported for patients entered into phase III trials, including those conducted in this unit Steiner et al., 1983; Amiel et al., 1984; Richards et al., 1992) . For example, the response to anthracyclines (40%) is lower than that reported in several randomised trials Steiner et al., 1983; Amiel et al., 1984; Perry et al., 1987; Italian Multicentre Breast Study with Epirubicin, 1988; Namer et al., 1990; Perez et al., 1991; Richards et al., 1992) , probably because patients with liver metastases and markedly abnormal liver biochemistry have been included in this study (Twelves et al., 1989; Twelves et al., 1991) .
The higher response rates observed with anthracyclines compared to other combinations in this study may in part reflect patient selection, although the observation is consistent with the high activity and probable survival benefits seen with doxorubicin and epirubicin in this disease (A'Hern et al., 1993) . The other factors which were found to be related to first response, TTP and survival following first-line chemotherapy for advanced disease are similar to those identified in three other large studies of patients with metastatic breast cancer (Swenerton et al., 1979; Namer et al., 1990; Falkson et al., 1991) . In all four studies initial disease free interval and liver metastases (or, (Falkson et al., 1991) . However, it remains impossible to exclude a reasonable possibility of worthwhile response in individual patients. Although administration of previous adjuvant CMF was not found to be predictive for subsequent TTP after chemotherapy, the P-value (0.07) was of borderline significance. This result is not therefore in conflict with the results of a recent publication from this centre in which there was a small but significant (P = 0.03) decrease in TTP for patients who had received previous adjuvant CMF (Houston et al., 1993) . Histological grade was the main factor from initial presen- tation with breast cancer which predicted for survival after chemotherapy; this may be because this factor relates to the tumour's growth rate, and thus carries prognostic significance throughout the tumour's history. We have confirmed that response rates and TTP following second line chemotherapy are lower than those for first line treatment. Methods for selecting patients who are likely to benefit from second line or subsequent chemotherapies have previously received little attention. Approximately one third of our patients who had received first line chemotherapy went on to receive further chemotherapy. This group included substantial numbers of patients who had experienced objective response, stable disease and progressive disease following first line therapy. As might have been expected, those who had previously responded had a higher response rate with second line therapy. However, this effect was relatively small. Perhaps surprisingly, time to progression after first line chemotherapy was not an indicator of TTP following second line therapy. Thus, although the probability of a second response can be estimated, it remains impossible to predict which individual patients are likely to derive benefit from such treatment.
In conclusion, although 30%-40% of patients will respond to chemotherapy, it is difficult to identify such patients on the basis of currently available prognostic factors. For second-line and later chemotherapies the response rate is smaller, with some 15%-20% achieving an objective response, but still no useful predictive factors to identify this group. It would seem therefore, that a clinically based judgement for each individual is still the only way of deciding whether or not to give chemotherapy for advanced breast cancer, and that it will be necessary to go on treating patients with the expectation that many of them will receive no benefit from the treatment. For the patient, deciding whether to have a particular treatment or not can be a difficult and highly subjective decision (Slevin et al., 1990) . These results may enable clinicians to provide patients with better information on which to make this decision in advanced breast cancer.
